Vertex bets $10B on Crinetics to reshape endocrinology portfolio

TL;DR Summary
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, marking the largest deal in Vertex’s history and expanding its commercial endocrinology portfolio with Crinetics’ programs in obesity, diabetes and related endocrine diseases.
Topics:business#biotech-acquisition#crinetics-pharmaceuticals#deals#endocrinology#pharmaceutical-merger#vertex-pharmaceuticals
- Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics Endpoints News
- Vertex to Buy Crinetics for $10 Billion in Biggest Deal Yet Bloomberg.com
- Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion WSJ
- CRNX Stock Soars Nearly 100% After-Hours On Vertex's $10B Acquisition Yahoo Finance
- Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms STAT
Reading Insights
Total Reads
1
Unique Readers
8
Time Saved
3 min
vs 4 min read
Condensed
95%
611 → 33 words
Want the full story? Read the original article
Read on Endpoints News